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Specialty Update
What’s New in Spine Surgery
By Keith H. Bridwell, MD, Paul A. Anderson, MD, Scott D. Boden, MD, Alexander R. Vaccaro, MD, and Jeffrey C. Wang, MD
What’s New in the Treatment 
of the Cervical Spine
The results of randomized controlled trials of several cervical 
arthroplasty devices are becoming available and are the focus 
of much attention. At the same time, secondary outcomes are 
being analyzed that may address socioeconomic concerns 
about the costs and observable benefits of arthroplasty. Since 
the introduction of a validated outcome tool to measure swal-
lowing dysfunction, researchers have more critically analyzed 
postoperative dysphagia. With the continued expansion of the 
use of cervical laminoplasty, methods to reduce complica-
tions continue to be explored.
Disc Arthroplasty
Disc arthroplasty is currently undergoing rigorous clinical 
testing, and the outcomes of this procedure are being com-
pared with those of fusion in randomized controlled trials. 
The inclusion criteria are single level radiculopathy or myel-
opathy, failure of nonoperative management, adult age, and 
the absence of significant instability or severe spondylosis or 
facet disease. Full reports on these trials are not yet available. 
However, pooled results from several investigation sites have 
been presented for three different prostheses. All studies have 
shown significant improvements in outcome measures for 
both fusion and experimental groups. With arthroplasty, the 
mean range of motion has increased by 1° to 2° and the rates 
of complications related to the procedure have been low, with 
no differences compared with controls. Two studies evaluating 
titanium polyurethane and stainless steel metal-on-metal 
prostheses demonstrated that the pooled site outcomes were 
significantly better for the arthroplasty group than for the fu-
sion group with regard to pain, disability, and overall success. 
Six-year outcomes from Europe are encouraging, with pa-
tients maintaining clinical improvement and motion. Adja-
cent-segment disease appears to progress in patients with 
preexisting disease but not in its absence.
From outside the United States, there have been case 
reports of complications, including the late development of 
central stenosis secondary to osteophyte formation, fracture 
of a vertebral body during insertion, spontaneous fusion, ex-
pulsion of the device, and kyphotic angulation. Despite these 
cases, the results of disc arthroplasty are encouraging, but 
longer follow-up is needed.
Early return to function is a hypothetical benefit of 
arthroplasty. In general, arthroplasty does not require im-
mobilization and patients are allowed to rapidly return to full 
function. The median time to return to work is significantly 
better following arthroplasty than it is following fusion. This 
effect is even greater in patients receiving Workers’ Compen-
sation. From a socioeconomic perspective, this may mitigate 
the additional cost of the implant and the additional surgical 
time.
Complications
Wang et al. reported on the complications and mortality as-
sociated with surgical treatment in patients with degenerative 
cervical spine disease. That study was a retrospective analysis 
of the Nationwide Inpatient Sample (a sample of hospital dis-
charges). Over a ten-year period, 0.3% of hospital admissions 
were for the treatment of cervical spine disease. Complica-
tions based on specific disease codes were present in 3.9% of 
the patients, with an overall mortality rate of 0.14%. Multi-
variate analysis identified risk factors for complications, in-
cluding age (more than seventy-four years), a diagnosis of 
myelopathy, a posterior fusion alone, or combined anterior-
posterior fusion.
Dysphagia is an under-recognized morbidity after ante-
rior cervical surgery. Using an accepted outcome instrument, 
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Lee et al. found that dysphagia was present in >50% of pa-
tients at one month and as many as 15% at two years. Risk 
factors included female gender, revision procedures, and mul-
tilevel procedures. Ischemia of the upper esophageal sphinc-
ter mucosa resulting from the use of soft-tissue retractors may 
be the cause of postoperative dysphagia. Maintaining the en-
dotracheal balloon pressures at <20 mm Hg, intermittent re-
laxation of retractors, and cuff reinflation after the retractors 
are placed are all strategies that may decrease dysphagia.
Myelopathy
Expansive laminoplasty for decompression in patients with 
multilevel spinal cord stenosis and myelopathy generally has 
been shown to have an outcome similar to that of anterior 
decompression and fusion. Laminoplasty avoids problems 
with fusion but has been associated with kyphotic deformity 
and chronic neck pain. A number of strategies have been 
described to decrease this tendency. Liu et al. preserved the 
spinous process-ligament-muscle complex with use of an os-
teotomy at the base of the spinous process reconstructed with 
wire fixation. Thirty patients had a mean increase of 9° of 
lordosis, and no patient had increased kyphosis. Other ap-
proaches to minimize neck pain include avoiding C7 lamino-
plasty altogether and performing a laminectomy rather that 
a laminoplasty at C3; this affords greater retention of the 
musculature attachments to C2. These techniques have been 
associated with diminished axial pain in case series. Their ac-
ceptance will require better-designed studies to prove their 
safety and efficacy.
In the study by Miyata, forty patients who had post-
operative ossification of the posterior longitudinal ligament 
following a French-door type of laminoplasty were evaluated 
with dynamic magnetic resonance imaging. The author found 
that the cord had shifted posteriorly and was adequately de-
compressed. This study again validates that posterior decom-
pression allows posterior cord translation away from the 
ventral pathology.
Despite surgical treatment, ossification of the posterior 
longitudinal ligament appears to progress in the majority of 
patients and can lead to recurrent symptoms. No means to 
decrease this tendency have been developed. Furthermore, 
it is not known if fusion will likely increase or decrease this 
phenomenon.
An important controversy is how to treat and counsel 
patients who have cervical stenosis but are asymptomatic. 
Recent reports from the Cervical Spine Research Society have 
shown that 30% of patients with stenosis experienced minor 
trauma and that half of those will deteriorate neurologically. 
Future studies should determine if a much more aggressive 
surgical approach can prevent neural damage.
Spinal Cord Monitoring
Intraoperative neurophysiologic monitoring during cervical 
spine surgery has not been shown to increase patient safety or 
to have a positive cost benefit. Smith et al. reviewed 1039 cases 
of decompression for non-myelopathy monitored with soma-
tosensory evoked potentials and found a 1% incidence of any 
changes. All changes in somatosensory evoked potentials were 
corrected by normalizing blood pressure. There was one non-
detected cord deficit, and no differences were identified be-
tween patients who were monitored and those who were not. 
In patients with myelopathy, transcranial motor evoked po-
tentials appear to identify C5 nerve root lesions in a majority 
of cases, although they have not been shown to be useful in 
preventing injury to this nerve root.
What’s New in Biologic 
Topics Related to the Spine
Biologic tools for reconstruction and regeneration continue 
to be an important focus of research related to the spine today. 
There are continued efforts to enhance the process of achiev-
ing spine fusion and to eliminate the need for autogenous iliac 
crest bone graft harvest. Since the United States Food and 
Drug Administration’s (FDA) post-marketing approval of re-
combinant human bone morphogenetic protein-2 (rhBMP-2) 
in 2002 and the creation of a Humanitarian Device Exemption 
for rhBMP-7 late in 2004, the era of recombinant bone mor-
phogenetic proteins for use in spine fusion has continued to 
blossom. Given the limited access (with only two companies 
producing approved BMPs) as well as their relatively high 
cost, there has been renewed interest in promoting less ex-
pensive and potentially unvalidated alternative bone-graft 
substitutes. Finally, while an increasing amount of research 
continues to be focused on understanding the biology of the 
intervertebral disc and on developing biologic strategies to re-
tard or reverse degeneration, these treatments still seem to be 
quite far from clinical practice.
Recombinant Osteoinductive Proteins
The initial clinical studies on the use of rhBMP-7 (OP-1; 
Stryker Biotech, Hopkinton, Massachusetts) for posterolat-
eral spine fusion yielded fusion success rates of 50% to 70% 
on radiographs, and these modest fusion rates were attributed 
to the use of a “more challenging” noninstrumented spine 
fusion model. In 2006, nineteen patients with degenerative 
spondylolisthesis were entered into a prospective, random-
ized, controlled study of instrumented fusion. Patients were 
randomized to receive OP-1 putty alone (3.5 mg of OP-1 per 
side) or local autograft with hydroxyapatite-tricalcium phos-
phate granules. The fusions were evaluated with plain radio-
graphs and computed tomographic scans. Sixteen patients 
who showed radiographic evidence of fusion underwent in-
strumentation removal and surgical exploration of the fusion 
site. Although seven of the nine patients managed with OP-1 
were thought to have fusion on the radiographs, only four of 
the seven actually had fusion at the time of exploration, for an 
overall OP-1 fusion rate of four of nine. In contrast, nine of 
the ten control patients who were managed with local bone 
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graft were thought to have fusion on radiographs and seven 
of the nine actually had fusion at the time of exploration, for 
an overall autograft fusion rate of seven of ten. Although this 
difference was not significant because the study was under-
powered, the fusion rate of approximately 50% associated 
with the use of OP-1 in patients managed with an instru-
mented fusion is consistent with the numbers reported in 
studies of uninstrumented fusion and is still not at a level 
equal or superior to that of autograft. It is believed that the 
data from the OP-1 posterolateral United States clinical trial 
will remain under review by the FDA for consideration for 
post-marketing approval.
Although rhBMP-2 (INFUSE; Medtronic Sofamor 
Danek, Memphis, Tennessee) has been approved by the 
FDA for anterior lumbar interbody fusion, much physician-
directed use has occurred in the posterolateral spine. A sub-
set of data from an investigational device exemption study 
involving the use of a higher concentration of rhBMP-2 
(20 mg BMP-2 per side) on a compression-resistant matrix 
(AMPLIFY; Medtronic) has been published. The report in-
cluded ninety-eight patients from a prospective, randomized 
study in which AMPLIFY was compared with iliac crest bone 
graft in patients undergoing a single level instrumented pos-
terolateral lumbar fusion. In this subset of patients, the radio-
graphic fusion rate was 88% for the AMPLIFY group and 73% 
for the iliac crest bone graft group (p = 0.05). This was the 
first time that a recombinant BMP demonstrated superiority 
over autogenous bone graft. With the outcome measures used, 
no substantial clinical benefit was detected in association with 
the avoidance of harvesting an iliac crest bone graft. Readers 
should note that the BMP formulation comprising AMPLIFY 
is different (with respect to dose and carrier) than the cur-
rently available INFUSE formulation. In another study, the 
approved INFUSE kit was used in addition to iliac crest can-
cellous bone graft for instrumented posterolateral fusion. 
The use of INFUSE in combination with iliac crest bone im-
proved the fusion success rate (as determined with thin-slice 
computed tomography scans) from 77% with iliac crest graft 
alone to 97% with iliac crest graft plus one large InFuse kit 
(6 mg BMP-2 per side) wrapped around local bone as a bulk-
ing agent. This finding suggests that the current kit, while 
likely not sufficient as a stand-alone graft substitute for the 
posterolateral spine, can provide a significant enhancer effect, 
improving the success of autogenous bone graft.
A primary concern with off-label use of recombinant 
BMPs relates to local adverse events. The three most com-
monly reported local side effects have been heterotopic bone 
formation in the surgical approach track, transient bone re-
sorption when used near exposed cancellous bone, and sterile 
seroma fluid collections and/or local edema. Most of these 
local side effects are believed to be related to the surgeon’s use 
of too much BMP either by increasing the concentration of 
the growth factor or by overstuffing the defect, which can re-
sult in a higher concentration or leakage of BMP into the sur-
rounding tissues. Two reports have described perioperative 
swelling in the cervical spine, again most often in association 
with excessive BMP doses and with the implant being placed 
outside the structural cage or ring. Surgeons who are encoun-
tering these local side effects with any regularity should care-
fully examine their technique to limit the exposure of BMP 
directly to cancellous bone (e.g., through less aggressive end 
plate decortication) and should avoid the use of excessive 
amounts of BMPs in small spaces or overpacking of the BMP 
implants.
Other Bone-Graft Substitutes
Although much focus remains on recombinant osteoinductive 
proteins, their relatively high cost has continued to encourage 
research involving other bone-grafting solutions. A recently 
published study demonstrated the failure of platelet concen-
trates to improve spine fusion healing. This study adds to a 
growing body of literature suggesting that platelet gels either 
inhibit or have no effect on spine fusion healing. In addition, 
an animal study confirmed that platelet-derived growth factor, 
transforming growth factor-beta, and platelet gel inhibited the 
BMP activity in demineralized bone when implanted together 
in animals. While platelet gels may serve a purpose for im-
paired wound-healing, their role in promoting bone forma-
tion remains in question.
A recently published animal study investigated the role 
of simvastatin in achieving posterolateral spine fusion in rab-
bits. Statins have been shown to increase the expression of 
BMPs and may enhance bone formation in certain situations. 
In this study, the systemic administration of simvastatin did not 
positively or negatively affect spine fusion. It is possible that 
local administration of statins may have more profound effects.
Interest in mesenchymal stem cells has increased with 
the introduction of two mineralized allograft products that 
are claimed to have cryopreserved stem cells. These products 
are claimed to immunodeplete the non-stem cells from al-
lograft and to provide a mineralized scaffold with allogeneic 
stem cells. Since these products are regulated as “minimally 
manipulated tissues,” little outcome data are available. The 
studies that are under way may not include the proper con-
trols to assess whether the stem cells are providing any in-
creased healing in comparison with the allograft alone. These, 
as well as other, minimally manipulated products that are 
claimed to have bone-healing potential must be carefully 
evaluated by surgeons because the FDA does not require de-
finitive proof of bone-enhancing capability. In general, the 
number of stem cells present in bone marrow is relatively 
small, and without specific signals (e.g., BMP) it is not clear 
whether sufficient numbers of cells are present to initiate bone 
formation de novo.
Biologic Treatments for Disc Degeneration
Progress toward biologic treatments to prevent or retard disc 
degeneration continued at a slow pace. Continued evidence of 
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beneficial effects of recombinant BMPs (BMP-7, BMP-2, 
growth differentiation factor-5) on disc metabolism in ani-
mals has prompted the planning of a clinical trial to investi-
gate the response in humans. A majority of this preclinical 
work has been performed with OP-1, which can prevent disc 
height loss after needle puncture injury and can restore disc 
height that has been already lost after anular puncture in rab-
bits. Although this technology is a long way from clinical use, 
it is worth monitoring developments in this area, which could 
ultimately provide a groundbreaking technology for the treat-
ment and prevention of many degenerative spine disorders.
What’s New in Spinal 
Deformity Surgery
Over the past year, many articles and presentations addressed 
the etiology of adolescent idiopathic scoliosis and the treat-
ment of early-onset scoliosis as well as congenital spinal defor-
mity, particularly thoracic insufficiency syndrome. There also 
have been advances in the treatment of kyphosis, neuromus-
cular scoliosis, and spondylolisthesis. The Scoliosis Research 
Society (SRS) continues to be very interested in investigating 
complications of surgical treatment.
Etiology of Adolescent Idiopathic Scoliosis
Investigators from two centers presented papers at the recent 
SRS meeting that further emphasized the potential genetic 
markers and familial characteristics of idiopathic scoliosis. 
Identification of the etiology of idiopathic scoliosis remains 
the number-one research goal of the SRS.
Early-Onset Scoliosis
Several new methods are evolving to allow for continued 
growth with intermittent surgical lengthening of the spine for 
patients with infantile and juvenile scoliosis. Such techniques 
utilize bilateral instrumentation, intermittent distraction, and 
multiple fixation points at the top and bottom and potentially 
at the apex of the deformity.
Congenital Spinal Deformity
The “titanium rib” technique with expansion thoracostomy 
has continued to gain popularity and momentum. Early data 
continue to suggest that distraction techniques associated 
with chest wall surgery can slowly lengthen the spine with-
out creating a major neurologic deficit and with modest im-
provement in chest volumes. Documentation of changes in 
pulmonary function in these patients is not straightforward, 
however. One study, conducted at The Children’s Hospital 
of Philadelphia, did not demonstrate a significant improve-
ment in lung function after expansion thoracostomy surgery. 
According to one multicenter study presented at the SRS 
meeting, patients with thoracic insufficiency syndrome 
clearly had marked reduction in their quality of life when 
compared with other children on the basis of the Child 
Health Questionnaire.
Kyphosis
One excellent paper that was presented at the SRS annual 
meeting emphasized the risk of increased kyphosis and pain 
following implant removal because of idiopathic scoliosis. 
Previous presentations have emphasized the problems associ-
ated with implant removal in the adult population. It appears 
that this is a substantial concern in the teenage population as 
well. The extent to which changes in the deformity reflected 
bending of the fusion mass as opposed to motion at undetec-
ted pseudarthroses was not entirely clear.
Neuromuscular Scoliosis
Assessment of the benefits of surgical treatment for patients 
with cerebral palsy and spinal deformity is quite complex. 
Most previous studies have only assessed radiographic param-
eters as opposed to a patient/parent evaluation. One paper 
that was presented at the SRS meeting focused on eighty-one 
children with cerebral palsy (and their families) who were 
undergoing spinal fusion. The postoperative complication 
rate was high (33%). However, the family satisfaction rate 
was quite high (92%). Eighty-seven percent reported im-
provement in sitting balance, and 66% believed that quality 
of life had improved. Unfortunately, at this time, health-
related quality-of-life measures for this population of pa-
tients are not standardized and validated.
Spondylolisthesis
Classification of spondylolisthesis has remained elusive. Au-
thors from Boston, Montreal, and France, as part of a multi-
center study, have identified two distinct groups regarding the 
sagittal alignment of patients with high-grade spondylolisthe-
sis. Critical factors appear to be the orientation of the pelvis 
and the sacrum, the obliquity of the L5-S1 disc, and the degree 
of dysplasia of the L5 element.
Adolescent Spinal Deformity
There continues to be a substantial effort to investigate the 
results associated with the use of pedicle screw implants, par-
ticularly in the thoracic spine, for the treatment of adolescent 
idiopathic scoliosis. Most data suggest that correction is some-
what better in association with this technique than in associa-
tion with techniques involving the use of either hooks or wires 
or a combination of hooks, wires, and screws. It appears that 
Cobb angle correction, translational correction, and rota-
tional correction are all slightly better with pedicle screws than 
with other implants. Furthermore, for curves of between 70° 
and 100°, it appears that anterior and thoracoscopic releases 
frequently are not required if pedicle screw implants are used 
to achieve fixation at all levels. In terms of cost analysis, pedi-
cle screw implants are expensive, but if they obviate the need 
for open or thoracoscopic anterior releases, this is offset by the 
shorter operating time, decreased surgical morbidity, and 
fewer days spent in the hospital and the intensive care unit 
than is the case with a combined approach. One potential dis-
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advantage of the pedicle screw technique is that the hypoky-
photic thoracic spine remains hypokyphotic postoperatively 
as most of the pedicle screw derotational techniques being 
employed now push anteriorly on the posterior convex spine. 
Furthermore, there is no clear evidence that the increased cor-
rection achieved with pedicle screw implants translates to 
higher Health Related Quality of Life scores on SRS surveys.
Adult Spinal Deformity
An SRS classification system for adult spinal deformity con-
tinues to evolve. This work is being accomplished by the Adult 
Spinal Deformity Committee of the SRS, led by Thomas Lowe, 
MD. The aspects of the classification include curve type, 
sagittl modifiers, distal lumbar degenerative modifiers, and 
global balance parameters. In addition, Frank Schwab, MD, 
has a very similar classification scheme, which is reflective of 
the likelihood of surgical intervention. Factors that predict 
the need for surgical treatment of adult scoliosis include sagit-
tal and coronal plane decompensation, substantial rotatory 
subluxations, spinal stenosis symptoms, and deformity pro-
gression. The coronal Cobb angle itself is not a primary 
determinant for surgical intervention. It does appear the 
SRS Health Related Quality of Life instrument is far more 
responsive to change following the surgical treatment of adult 
spinal deformity than it is following the surgical treatment of 
adolescent deformity. With adolescent deformity, it appears 
that the only domain that substantially changes after surgery is 
the self-image domain, whereas with adult spinal deformity, 
changes typically are identified in all domains.
Complications after surgery for the correction of spinal 
deformity are more common in adults than in adolescents. 
These complications include pseudarthrosis, proximal and 
distal junctional kyphosis, and an extended recovery. RhBMP 
is being considered as an alternative or adjunct to reduce the 
pseudarthrosis rate in adults with spinal deformity. However, 
use of these products for posterior surgery constitutes an off-
label use and is prohibitively expensive for many centers.
Complications
The Morbidity and Mortality Committee report to the mem-
bership at the annual SRS meeting was an exhaustive study of 
the complications of spinal fusion for the treatment of adult 
scoliosis. Adult patients who had idiopathic scoliosis were com-
pared with those who had scoliosis of a purely degenerative ori-
gin. From 2003 to 2005, 2852 patients underwent spinal fusion 
for the treatment of adult scoliosis. The complication rate was 
significantly higher in the degenerative group than in the idio-
pathic group (15.6% compared with 12.3%; p < 0.01). The 
death rate was the same in both groups. The neurologic compli-
cation rate was 1.3% overall, with six documented spinal cord 
deficits (0.21%), but only one deficit was complete (0.04%).
What’s New in Spinal Cord Injury
Research in the area of spinal cord injury is making strides in 
understanding the mechanisms of secondary injury and the fac-
tors inhibiting axonal regeneration. Cell death not only occurs 
at the time of injury but also is due to a cascade of secondary 
events that result in further neurologic dysfunction. Multiple 
biochemical processes, including the production of reactive ox-
ygen species, excitotoxicity from neurotransmitter release, and 
imbalances in ion concentrations at a cellular level, culminate in 
the death of neurons and supporting glial cells. 
Spinal cord injury is followed by changes that inhibit the 
regrowth of axons and the reestablishment of neural connec-
tions. It was once thought that axonal regeneration could not 
occur within the central nervous system, but it is now under-
stood that central nervous system axons can regenerate in the 
proper environment. Formation of a glial scar and production 
of inhibitory compounds in the extracellular matrix impede 
the regrowth of axons across the site of injury.
As a result of a better understanding of the multiple bio-
chemical processes that result in secondary cell injury and the 
inhibition of axonal regeneration, many new therapies are be-
ing studied. In addition, new strategies are being investigated 
to bridge the gap across a damaged spinal cord segment.
Therapies to Reduce Secondary Injury
Historically, the investigation of spinal cord injury therapies 
has focused on the inhibition of lipid peroxidation and the 
use of anti-inflammatory drugs, but through a better under-
standing of the mechanisms leading to secondary injury, new 
investigational agents have targeted multiple areas of the bio-
chemical cascades that lead to cell death. Calpain and caspase 
proteases are both upregulated and associated with secondary 
injury cascades in spinal cord injury. Recent studies on 6-
shogaol, an apoptotic inhibitor, have shown significant im-
provements in hind-limb function in rodent models. Eryth-
ropoietin (EPO) and derivatives of this compound exert an 
anti-apoptotic effect in the setting of hypoxia and have been 
shown to improve cell survival after ischemic brain injury 
and spinal cord injury in rodent models. Polyethylene glycol 
(PEG), which is thought to interact with and stabilize in-
jured cell membranes, has been shown to have neuroprotec-
tive properties in spinal cord injury models. Minocycline has 
been shown to have potent anti-inflammatory and neuro-
protective properties after spinal cord injury and is cur-
rently being investigated in a preliminary clinical trial in 
Canada. Growth factors also have been studied extensively 
as a means to reduce secondary injury and also to improve 
nerve regeneration. Growth factors administered directly at 
the site of experimental spinal cord injury or via gene thera-
pies have been shown to reduce cell death and to improve ax-
onal regeneration.
Therapies to Promote Axonal Regeneration
Two therapies to promote axonal regeneration have been 
evaluated in clinical trials over the last three years, and a 
number of other potential therapies are being evaluated 
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in laboratory studies. Rho, a small signaling protein, has 
been shown to result in the inhibition of axonal regeneration 
after experimental spinal cord injury. C3 transferase (C3), 
an inhibitor of Rho, was shown to have neuroprotective 
and regenerative properties in animal models. Cethrin (Bio-
Axone Therapeutic, Saint-Laurent, Quebec), a combination 
of C3 with a transport sequence that helps the protein to 
cross cell membranes, showed encouraging results in a re-
cent Phase-I/IIa multicenter clinical trial. The application 
of Cethrin in the epidural space at the time of decompressive 
or stabilization surgery in thirty-seven patients with Ameri-
can Spinal Injury Association (ASIA) type-A injuries re-
sulted in improvement of at least one ASIA grade in 30% of 
the patients within six weeks. Historically, <5% of patients 
with an ASIA type-A lesion will have any improvement. 
Obviously, that study was small, but it warrants further 
clinical studies.
Although much research has been focused on reducing 
the immune response to spinal cord injury, other approaches 
have involved the utilization of immune cells (macrophages) 
to facilitate axonal regeneration. Animal testing with geneti-
cally modified autologous macrophages showed encouraging 
results in rodent models and prompted human clinical stud-
ies. ProCord (Proneuron Biotechnologies, Los Angeles, 
California) therapy, involving the injection of “activated” 
autologous macrophages into the contused area of a spinal 
cord injury, was begun as a Phase-II clinical study in the 
United States and Israel. The trial, which enrolled twenty-four 
patients, was suspended from further patient recruitment be-
cause of funding issues, but the patients who were managed 
are still being followed.
Other investigations have targeted neurite growth in-
hibitory protein, Nogo-A, which is a cell surface protein, ex-
pressed after spinal cord injury, that inhibits neurite growth. 
Antibodies to Nogo-A have been administered intrathecally in 
rodent spinal cord injury models, with increasing axonal re-
generation and improved neurologic recovery being noted. 
Rolipram, a specific inhibitor of phosphodiesterase 4, has also 
been shown to improve axonal regeneration after spinal cord 
injury in rodent models.
Cell-based therapies involving Schwann cells, olfactory 
ensheathing cells, and stem cells as well as other forms of 
implantable scaffolding have been shown to facilitate axonal 
regeneration and remyelination after spinal cord injury in 
animal models. Lima et al. recently reported on the implan-
tation of olfactory mucosa at the site of injury in seven pa-
tients with an acute complete spinal cord injury and noted 
an improvement in the ASIA grade in all patients, with two 
patients having two grades of improvement. Implantation 
of stem cells has received substantial attention in the media 
as a potential cure for spinal cord injury. However, as en-
couraging as the results in animal studies have been, human 
clinical trials have not proven that these therapies are cur-
rently effective.
What’s New in the Treatment 
of the Lumbar Spine
Novel treatments and advances in the treatment of lumbar 
degenerative disorders continue to be of high interest to clini-
cians and researchers as these pathologies represent some of 
the more common musculoskeletal disorders. The develop-
ment of novel technologies is very exciting, but we certainly 
need appropriate evidence of their efficacy.
Motion Preservation/Lumbar Disc Arthroplasty
The area of motion preservation of the lumbar spine—speci-
fically, disc arthroplasty—continues to be a topic of high in-
terest, and several studies have evaluated the efficacy of the 
treatments. Zigler et al., in a presentation of the slightly 
longer-term follow-up of their prospective randomized study 
of one prosthesis, compared the results of arthroplasty with 
those of fusion. The minimum duration of follow-up was two 
years, with some patients being followed for as long as three 
years. These early results showed that disc arthroplasty was as 
good as fusion, with some early differences favoring disc ar-
throplasty in terms of the pain score and patient satisfaction 
disappearing by the third year.
One group of investigators presented a systematic litera-
ture review on the efficacy and safety of intervertebral disc 
prostheses for the lumbar spine. This meta-analysis primarily 
examined two of the FDA-approved disc devices in compari-
son with fusion. The conclusions were that the scientific evi-
dence presently available for these devices was not sufficient to 
recommend the use of either one for the treatment of lumbar 
disc pain in routine clinical practice. The authors recom-
mended additional studies with larger numbers of patients.
Adjacent Segment Degeneration
Theoretically, the greatest benefit of motion preservation over 
fusion would be a decrease in or the avoidance of adjacent-
segment disease. However, the delineation of the prevalence 
of adjacent-segment disease is critically important. In one 
prospective study of eighty patients undergoing an anterior 
interbody fusion at L5-S1, the two proximal adjacent levels 
were monitored for an average duration of follow-up of five 
years. The rate of advanced degeneration at either of these lev-
els was not significantly changed from the initial preoperative 
rate. The authors concluded that adjacent-segment disease af-
ter anterior interbody fusion is not a clinical problem.
Two studies have examined the fate of the L5-S1 level 
following spine fusion to L5. One study evaluated nineteen 
patients with fusion to L5 and showed that 32% of the pa-
tients required revision of the fusion to the sacrum at the 
time of the five-year follow-up, and the investigators pre-
dicted a 60% survival rate at ten years of follow-up. Another 
center presented a study of thirty patients after five years of 
follow-up. The investigators noted a high rate (68%) of pro-
gressive degeneration at the L5-S1 level and noted a 20% rate 
of revision to the sacrum.
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Biological Promoters of Fusion
In addition to the review of biologics earlier in this update, 
three studies are particularly pertinent to the lumbar spine 
and will be discussed here. Dimar et al. reported the results 
of a prospective randomized study of 463 patients in which 
the use of rhBMP-2 was compared with autogenous bone 
graft for posterolateral lumbar fusion. The authors reported 
significant differences between the groups in terms of opera-
tive time and blood loss but not in terms of the length of hos-
pital stay. The fusion rates were similar in the two groups, but 
the rate of nonunion failure was higher in the autograft group 
than in the rhBMP-2 group.
Vaccaro et al. presented their results after the use of 
rhBMP-7 for uninstrumented posterolateral spinal fusion. 
Twenty-six patients were followed to the five-year time-
point, and the five-year results were compared with the 
earlier (two-year) results presented for a larger group. The 
authors reported that the fusion rates and clinical outcomes 
were maintained at the longer-term follow-up.
Angevine et al. studied the cost-effectiveness of the use 
of rhBMP-2 for the primary surgical treatment of adult scolio-
sis. This retrospective cohort cost-offset analysis examined the 
charges for each hospitalization at one institution for all adults 
undergoing this procedure. The investigators found that the 
use of rhBMP-2 increased the cost of the index procedure for 
adult idiopathic scoliosis, but was cost-neutral when control-
ling for the type of surgery, the number of levels, and the 
number of pedicle screws used. Furthermore, when taking 
into account the differential rate of pseudarthrosis and the 
associated costs, the use of rhBMP-2 was more cost-effective.
Nonoperative Care
Perhaps the most interesting and promising developments 
were related to the nonoperative treatment of lumbar spine 
abnormalities. One group of investigators presented the re-
sults of a prospective, randomized study of seventy-four pa-
tients with lumbosacral radiculopathy who were managed 
with oral administration of tumor necrosis factor-alpha 
(TNF-alpha) antagonists or placebo. Compared with placebo, 
the TNF-alpha antagonist showed a reduction in maximum 
daily leg pain over the first two weeks, but by three weeks there 
were no differences. Additional, longer-term study is needed 
to fully delineate the benefits of this approach.
One group reported on a prospective series of 346 pa-
tients receiving nerve root injections for the treatment of a 
variety of degenerative lumbar disorders. The investigators 
demonstrated efficacy and the avoidance of surgery in a large 
percentage of patients (in increasing order of efficacy) who 
had moderate disc herniations, degenerative spondylolisthe-
sis, spinal stenosis, isthmic spondylolisthesis, foraminal 
stenosis, degenerative scoliosis, and failed back syndrome. 
Poor outcomes were found in association with stenosis, ex-
traforaminal disc herniations, recurrent disc herniations, 
and failed back surgery when combined with instability.
Complications
Wound complications are always of concern. The identifica-
tion of possible risk factors for prevention was the topic of 
one study of 18,352 patients, which examined risk factors for 
wound dehiscence and deep and superficial infections. Sig-
nificant risk factors for wound complications, in order of 
increasing risk, included smoking, non-insulin-dependent 
diabetes mellitus, and insulin-dependent diabetes. The com-
bination of smoking and diabetic status further increased the 
risk, and great care should be exercised when treating these 
patients.
Evidence-Based Orthopaedics
The editorial staff of The Journal reviewed a large number of 
recently published research studies related to the musculoskel-
etal system that received a Level of Evidence grade of I. Over 
100 medical journals were reviewed to identify these articles, 
which all have high-quality study design. In addition to arti-
cles published previously in this journal or cited already in this 
Update, sixteen level-I articles were identified that were rele-
vant to spine surgery. A list of those titles is appended to this 
review after the standard bibliography. We have provided a 
brief commentary about each of the articles to help guide your 
further reading, in an evidence-based fashion, in this subspe-
cialty area.
Upcoming Meetings and Events 
Related to Spine Surgery
The forty-second annual meeting of the Scoliosis Research 
Society (SRS) will be held on September 5 through 8, 2007, 
at the Edinburgh International Conference Center, Edin-
burgh, Scotland. It will be preceded by a one-day course enti-
tled “Update on Congenital Spinal Deformity,” to be held on 
September 4, 2007. Web site: www.srs.org
The twenty-second annual meeting of the North Ameri-
can Spine Society (NASS) will be held on October 23 through 
27, 2007, at the Austin Convention Center in Austin, Texas. It 
will be preceded by several precourses and two half-day meet-
ings of the Biologics Research Section and the Motion Preser-
vation Section, which are being developed by the society. Web 
site: www.spine.org
The thirty-fifth annual meeting of the Cervical Spine 
Research Society (CSRS) will be held on November 29 
through December 1, 2007, at the Palace Hotel in San Fran-
cisco, California. It will be preceded by an Instructional 
Course sponsored by the Society on November 28, 2007. 
Web site: www.csrs.org
The Federation of Spine Associations will present the 
spine program at Specialty Day at the annual meeting of the 
American Academy of Orthopaedic Surgeons (AAOS), to be 
held on Saturday, March 8, 2008, in San Francisco, California. 
Web site: www.aaos.org
The annual meeting of the International Society for 
the Study of the Lumbar Spine (ISSLS) will be held May 
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25 though 31, 2008, in Geneva, Switzerland. Web site: 
www.issls.org
The thirty-fourth annual meeting of the American 
Spinal Injury Association (ASIA) will be held on June 19 
through 22, 2008, at Loews Coronado Bay Resort in San 
Diego, California. Web site: www.asia-spinalinjury.org
The fifteenth annual International Meeting on Ad-
vanced Spinal Techniques (IMAST) will be held on July 8 
through 11, 2008, at the Hong Kong Convention Center in 
Hong Kong, China. Web site: www.imastonline.com
NOTE: The authors thank Drs. Jim Harrop, Alan Hilibrand, Steve Mardjetko, Dan Riew, and 
Harvinder Sandhu for peer reviewing the sections of this manuscript.
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Evidence-Based Articles Related to Spine Surgery
Brox JI, Reikerås O, Nygaard Ø, Sørensen R, Indahl A, Holm I, Keller A, 
Ingebrigtsen T, Grundnes O, Lange JE, Friis A. Lumbar instrumented fusion 
compared with cognitive intervention and exercises in patients with chronic 
back pain after previous surgery for disc herniation: a prospective random-
ized controlled study. Pain. 2006;122:145-55.
In this study from Norway, spinal fusion was compared with a cogni-
tive intervention and exercise program following the “failure” of a previous 
disc herniation operation to relieve back pain. There was a 50% success rate in 
the fusion group and a 48% success rate in the cognitive intervention/exercise 
group. Depending on one’s perspective, either both modalities were equally ef-
fective or equally ineffective in this very difficult group of patients. This study 
suggests there is no “one answer” to the patient who has continued chronic 
low-back pain after previous surgery for the treatment of a disc herniation.
Clarke J, van Tulder M, Blomberg S, de Vet H, van der Heijden G, Bronfort G. 
Traction for low back pain with or without sciatica: an updated systematic 
review within the framework of the Cochrane collaboration. Spine. 2006;
31:1591-9.
This study was a review of the literature on traction. There was not 
sufficient evidence to recommend traction for patients with low-back pain or 
sciatica. Because most studies were underpowered, the literature does not al-
low a negative conclusion that traction is not effective.
Clarke JA, van Tulder MW, Blomberg SE, de Vet HC, van der Heijden GJ, 
Bronfort G. Traction for low-back pain with or without sciatica. Cochrane 
Database Syst Rev. 2005;(4):CD003010.
This paper identified twenty-four randomized clinical trials involving 
>2000 patients. Five of the trials were considered “high quality.” The authors 
concluded that there was conflicting evidence regarding the short-term effec-
tiveness of either continuous or intermittent traction as compared with pla-
cebo, sham treatment, or other treatments when managing patients who have 
either chronic low-back pain or a mixture of low-back pain and sciatica. This 
finding suggests that there is nothing “magical” about employing traction 
when physical therapy is being used to treat low-back pain.
de Graaf I, Prak A, Bierma-Zeinstra S, Thomas S, Peul W, Koes B. Diagnosis 
of lumbar spinal stenosis: a systematic review of the accuracy of diagnostic 
tests. Spine. 2006;31:1168-76.
This was a review of the literature for published articles examining diag-
nostic studies for spinal stenosis. The authors found twenty-four articles (fifteen 
on imaging tests, seven on clinical tests, and two on other diagnostic studies). 
The authors found that the published studies were of poor quality and were not 
directly comparable, and they concluded that no firm conclusions could be 
made regarding the different tests. The results of this study are not surprising as 
spinal stenosis is a clinical syndrome with a large number of varying symptoms 
that may all not be present in any particular patient. The diagnosis of spinal 
stenosis is determined by the clinician on the basis of a combination of the test 
results, the clinical information and history, and the imaging studies.
Finckh A, Zufferey P, Schurch MA, Balagué F, Waldburger M, So AK. Short-
term efficacy of intravenous pulse glucocorticoids in acute discogenic sciatica. 
A randomized controlled trial. Spine. 2006;31:377-81.
The authors performed a randomized controlled trial evaluating the 
use of a single intravenous bolus of methylprednisolone (500 mg) for the 
treatment of acute sciatica (duration of symptoms, less than six weeks). The 
authors noted a significant decrease in sciatic pain in association with the in-
travenous administration of methylprednisolone over the first twenty-four 
hours but noted that the effects were transient and of small magnitude. This 
study demonstrates that a high-dose intravenous bolus of steroids may pro-
vide some short-term pain relief and, thus, may allow patients to better par-
ticipate in physical therapy and other conservative modalities to relieve the 
symptoms of sciatica.
Freeman BJ, Fraser RD, Cain CM, Hall DJ, Chapple DC. A randomized, 
double-blind, controlled trial: intradiscal electrothermal therapy versus 
placebo for the treatment of chronic discogenic low back pain. Spine. 
2005;30:2369-78.
This was a randomized controlled study comparing intradiscal elec-
trothermal therapy (IDET) with sham treatment for patients with chronic low 
back pain. Thirty-eight patients were randomized to IDET, and nineteen were 
randomized to sham treatment. All patients had one or two-level degenerative 
low-back pain confirmed with magnetic resonance imaging and discography. 
At six months, no improvement from baseline was observed in either group, 
and no differences were present between the IDET and sham groups. This was 
a well-done study that contradicted a previous randomized controlled study 
that had demonstrated a slight to moderate effect of IDET as compared with 
sham treatment. Taking these studies together, IDET appears to have little 
clinical efficacy.
Gibson JN, Waddell G. Surgery for degenerative lumbar spondylosis: updated 
Cochrane Review. Spine. 2005;30:2312-20.
The authors performed an extensive review of the literature on the 
surgical treatment of degenerative lumbar spondylosis and concluded that 
there is a paucity of good studies on this topic. There is limited evidence to 
support some aspects of surgical practice. The authors underscored the im-
portance of critical appraisal of the literature when formulating individual 
practice behaviors.
Kääpä EH, Frantsi K, Sarna S, Malmivaara A. Multidisciplinary group reha-
bilitation versus individual physiotherapy for chronic nonspecific low back 
pain: a randomized trial. Spine. 2006;31:371-6.
This was a prospective randomized trial, from two different centers, 
that included 120 women who were employed as health-care and social-care 
professionals and had low-back pain. The women were randomized to either a 
multidisciplinary group rehabilitation program for seventy hours or individ-
ual therapy for ten hours. The authors found no differences between the two 
groups at the time of the two-year follow-up, with both groups demonstrating 
favorable effects from the therapy that held up at the time of the final follow-
up. The study shows that group therapy that is comprehensive is as effective as 
individual therapy and that both demonstrate positive effects at the time of 
two-year follow-up.
Khadilkar A, Milne S, Brosseau L, Wells G, Tugwell P, Robinson V, Shea B, 
Saginur M. Transcutaneous electrical nerve stimulation for the treatment of 
chronic low back pain: a systematic review. Spine. 2005;30:2657-66.
The authors set out to perform a meta-analysis of the literature on 
transcutaneous electrical nerve stimulation (TENS) for the treatment of low-
back pain but only found two studies that met criteria to include in this analy-
sis. They concluded that evidence to support the use of TENS treatment for 
low-back pain is limited.
Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Järvinen 
S, Niinimäki J, Veeger N, Seitsalo S, Hurri H. The treatment of disc hernia-
tion-induced sciatica with Infliximab: results of a randomized, controlled, 3-
month follow-up study. Spine. 2005;30:2724-8.
This was a prospective randomized controlled study of forty patients 
with sciatica due to a lumbar disc herniation. Patients were managed with ei-
ther a single infusion of the medication (antibody against TNF-alpha) or pla-
cebo. Both groups showed a significant reduction in leg pain, without any 
significant differences between the two groups. The authors concluded that 
there was no support for the use of this medication for lumbar disc hernia-
tion-induced sciatica. With the recent interest in TNF-alpha blockers for the 
treatment of sciatic pain, this study demonstrates that there was no difference 
between the medication and the placebo, which may reflect the positive natu-
ral history of the disorder itself.
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Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin 
M, Young B. Direct decompressive surgical resection in the treatment of spi-
nal cord compression caused by metastatic cancer: a randomised trial. Lancet. 
2005;366:643-8.
Patients with isolated epidural spinal metastases were randomized to 
radiation therapy or surgical decompression followed by postoperative irradi-
ation. The primary end point was the ability to walk. The study was discontin-
ued before full enrollment because the surgical group had significantly better 
results, including the percentage of patients who remained able to walk, the 
duration of walking, the number of patients who regained the ability to walk, 
and a decreased need for corticosteroids and opioids.
This convincing study demonstrates that for patients with isolated 
epidural spinal cord compression, surgery followed by radiation therapy is 
associated with a better outcome than radiation alone. This was true for pa-
tients with significant neurologic deficits and for those who were neurologi-
cally intact.
Rosenfeld M, Seferiadis A, Gunnarsson R. Active involvement and interven-
tion in patients exposed to whiplash trauma in automobile crashes reduces 
costs: a randomized, controlled clinical trial and health economic evaluation. 
Spine. 2006;31:1799-1804.
This randomized study demonstrated that for patients exposed to 
whiplash trauma in a motor-vehicle collision, active involvement and inter-
vention were both less costly and more effective than a standard intervention. 
There was reduced pain and less sick leave in the active involvement group.
Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA. Comparing yoga, 
exercise, and a self-care book for chronic low back pain: a randomized, con-
trolled trial. Ann Intern Med. 2005;143:849-56.
In this randomized controlled study of patients with prior episodic 
low-back pain, Viniyoga was compared with group exercise taught by a physi-
cal therapist or through an instructional booklet. Viniyoga is a safe technique 
that emphasizes breathing and posture for the treatment of low-back pain 
symptoms. At twenty-six weeks of follow-up, there was significant improve-
ment in both the exercise and yoga groups. The yoga group had superior out-
comes, but the differences were not significant compared with the exercise 
group. Both therapeutic groups had significantly better results than did the 
subjects who used the booklet. The conclusions of the study are limited in that 
the results cannot be generalized because the treatment population was 
poorly defined. Furthermore, instructions were given in each group by one 
practitioner who may have biased the outcome. The duration of follow-up 
was short, and it is unknown if the observed effect will be lasting. Finally, 
compliance with the program was not reported.
Singh K, Samartzis D, Strom J, Manning D, Campbell-Hupp M, Wetzel FT, 
Gupta P, Phillips FM. A prospective, randomized, double-blind study evalu-
ating the efficacy of postoperative continuous local anesthetic infusion at the 
iliac crest bone graft site after spinal arthrodesis. Spine. 2005;30:2477-83.
Continuous infusion of local anesthetic has been developed to de-
crease postoperative pain and is used in many surgical disciplines. This study 
tested its efficacy in patients undergoing spinal fusion with use of iliac crest 
bone grafts. Thirty-seven patients were randomized to placebo (saline solu-
tion infusion) or Marcaine (90 mL of 0.5%) with use of a continuous infusion 
technique. Significantly lower pain scores and less opioid consumption was 
present in the anesthetic group. No complications occurred in either group. 
The pump and anesthetics were cost-neutral. This was a well-done study 
showing the efficacy of an inexpensive (cost-neutral) method in decreasing 
postoperative pain. The use of this anesthetic technique should be considered 
in other musculoskeletal surgical areas.
Steele EJ, Dawson AP, Hiller JE. School-based interventions for spinal pain: a 
systematic review. Spine. 2006;31:226-33.
This was a systematic literature review of twelve papers. All twelve pa-
pers received a “weak quality rating”; therefore, no conclusions could be made 
regarding the effectiveness of a school-based spinal health intervention pro-
gram. This paper strongly suggests there is no clear evidence that schools and 
health-promotion programs help with the treatment of spinal pain. There is 
simply not a clear answer in the current peer-review literature.
Yukawa Y, Kato F, Ito K, Terashima T, Horie Y. A prospective randomized study 
of preemptive analgesia for postoperative pain in the patients undergoing poste-
rior lumbar interbody fusion: continuous subcutaneous morphine, continuous 
epidural morphine, and diclofenac sodium. Spine. 2005;30:2357-61.
The authors studied the use of preoperative and postoperative con-
tinuous subcutaneous morphine, continuous epidural morphine, and di-
clofenac sodium in a prospective randomized fashion. The diclofenac 
treatment group had the lowest initial visual analog scale pain scores imme-
diately after surgery (p = 0.059) but required more supplemental analgesic 
medications in the first seventy-two hours after surgery (p = 0.013). The epi-
dural group had more side effects, most commonly nausea and vomiting, 
than the other groups (p = 0.015). This study is very relevant to the practice 
of spine surgery as effective postoperative analgesia improves patient out-
comes, reduces secondary complications by allowing for early mobilization, 
and shortens hospital stay. On the basis of the results of this study, it appears 
that the administration of continuous subcutaneous morphine might be a 
safe and useful approach for the treatment of postoperative pain after spinal 
surgery and warrants further study.
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